K Fizazi1, A Ulys2, L Sengeløv3, M Moe4, S Ladoire5, A Thiery-Vuillemin6, A Flechon7, A Guida8, J Bellmunt9, M A Climent10, S Chowdhury11, H Dumez12, M Matouskova13, N Penel14, S Liutkauskiene15, L Stachurski16, C N Sternberg17, F Baton18, N Germann18, G Daugaard19. 1. Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr. 2. National Cancer Institute, Vilnius, Lithuania. 3. Department of Oncology, Herlev Hospital, Herlev. 4. Department of Oncology, Aalborg University Hospital, Aalborg, Denmark. 5. Department of Medical Oncology, Centre Georges François Leclerc, Dijon. 6. INSERM, UMR1098, Besançon. 7. Medicine, Centre Léon Bérard, Lyon, France. 8. Department of Oncology & Hematology, Azienda University Hospital, Modena, Italy. 9. Dana-Farber/Brigham and Women's Cancer Center, Boston, USA. 10. Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. 11. Guy's and St Thomas' NHS Foundation Trust, London, UK. 12. Department of General Medical Oncology, University Hospitals Leuven, Leuven; KU Leuven, Leuven, Belgium. 13. Urocentrum, Prague, Czech Republic. 14. General Oncology Department, Centre Oscar Lambret, Lille, France. 15. Lithuanian University of Health Sciences Hospital, Kaunas, Lithuania. 16. Gabinet Urologiczny, Gdynia, Gdańsk, Poland. 17. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. 18. Ipsen Innovation, Les Ulis, France. 19. Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Abstract
BACKGROUND: This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. PATIENTS AND METHODS: Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or placebo. The primary end point was radiologic progression-free survival (rPFS); secondary efficacy end points included: overall survival (OS); PFS on next-line therapy (PFS 2) and symptomatic PFS, assessed using the Brief Pain Inventory (BPI) questionnaire and analgesic use. Quality of life was measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and by the EuroQol-5 Dimension Quality of Life Instrument (EQ-5D). Adverse events were recorded. RESULTS: A total of 219 patients were screened and 144 patients randomized. The median duration of treatment was 18.7 weeks (range 0.6-102.7 weeks) for the tasquinimod arm and 19.2 weeks (range 0.4-80.0 weeks) for the placebo arm. Median (90% CI) rPFS was 31.7 (24.3-53.7) and 22.7 (16.1-25.9) weeks in the tasquinimod and placebo arms, respectively [HR (90% CI) 0.6 (0.4-0.9), P = 0.0162]. The median OS was not reached because only 14 deaths occurred by the cut-off date. No statistically significant differences between treatment arms were noted for symptomatic PFS, PFS 2, BPI score, FACT-P score, or EQ-5D. The incidence of any treatment emergent adverse event (TEAE) was similar in the tasquinimod and placebo arms (97.2% versus 94.3%, respectively), whereas severe TEAEs (NCI-CTC Grade 3-5) incidence was higher in the tasquinimod group (50.7% versus 27.1%). CONCLUSIONS: Randomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%. CLINICALTRIALS: gov identifier NCT01732549.
BACKGROUND: This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. PATIENTS AND METHODS: Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or placebo. The primary end point was radiologic progression-free survival (rPFS); secondary efficacy end points included: overall survival (OS); PFS on next-line therapy (PFS 2) and symptomatic PFS, assessed using the Brief Pain Inventory (BPI) questionnaire and analgesic use. Quality of life was measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and by the EuroQol-5 Dimension Quality of Life Instrument (EQ-5D). Adverse events were recorded. RESULTS: A total of 219 patients were screened and 144 patients randomized. The median duration of treatment was 18.7 weeks (range 0.6-102.7 weeks) for the tasquinimod arm and 19.2 weeks (range 0.4-80.0 weeks) for the placebo arm. Median (90% CI) rPFS was 31.7 (24.3-53.7) and 22.7 (16.1-25.9) weeks in the tasquinimod and placebo arms, respectively [HR (90% CI) 0.6 (0.4-0.9), P = 0.0162]. The median OS was not reached because only 14 deaths occurred by the cut-off date. No statistically significant differences between treatment arms were noted for symptomatic PFS, PFS 2, BPI score, FACT-P score, or EQ-5D. The incidence of any treatment emergent adverse event (TEAE) was similar in the tasquinimod and placebo arms (97.2% versus 94.3%, respectively), whereas severe TEAEs (NCI-CTC Grade 3-5) incidence was higher in the tasquinimod group (50.7% versus 27.1%). CONCLUSIONS: Randomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%. CLINICALTRIALS: gov identifier NCT01732549.
Authors: Roberto Pili; Michael Häggman; Walter M Stadler; Jeffrey R Gingrich; Vasileios J Assikis; Anders Björk; Orjan Nordle; Goran Forsberg; Michael A Carducci; Andrew J Armstrong Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: A J Armstrong; M Häggman; W M Stadler; J R Gingrich; V Assikis; J Polikoff; J E Damber; L Belkoff; Ö Nordle; G Forsberg; M A Carducci; R Pili Journal: Clin Cancer Res Date: 2013-11-19 Impact factor: 12.531
Authors: Richard Cathomas; Simon J Crabb; Michael Mark; Ralph Winterhalder; Christian Rothermundt; Tony Elliott; Philippe von Burg; Heike Kenner; Stefanie Hayoz; Simona Berardi Vilei; Daniel Rauch; Enrico Roggero; Markus G Mohaupt; Jürg Bernhard; Gabriela Manetsch; Silke Gillessen Journal: Prostate Date: 2016-07-25 Impact factor: 4.104
Authors: Urban Emmenegger; Christopher M Booth; Scott Berry; Srikala S Sridhar; Eric Winquist; Nesan Bandali; Annabelle Chow; Christina Lee; Ping Xu; Shan Man; Robert S Kerbel; Yoo-Joung Ko Journal: Oncologist Date: 2015-11-05
Authors: D E Gerber; S E Dahlberg; A B Sandler; D H Ahn; J H Schiller; J R Brahmer; D H Johnson Journal: Br J Cancer Date: 2013-08-13 Impact factor: 7.640
Authors: Clara Martori; Lidia Sanchez-Moral; Tony Paul; Juan Carlos Pardo; Albert Font; Vicenç Ruiz de Porras; Maria-Rosa Sarrias Journal: Cancers (Basel) Date: 2022-01-16 Impact factor: 6.639